Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics names Nicholas Maestas as Chief Financial Officer effective June 29, 2026

Neutral Impact 4 of 5 leadership Written later

Rani Therapeutics appointed Nicholas M. Maestas as Chief Financial Officer, succeeding Svai Sanford, who had previously announced he would step down once a successor was named. The company also approved a 2026 Equity Inducement Plan reserving 5,500,000 Class A shares for new-hire awards, which does not require stockholder approval.

Key points

  • Maestas, age 46, was CFO and Head of Corporate Strategy at Tempest Therapeutics from January 2025 until June 2026.
  • Offer letter dated June 24, 2026 sets an annual base salary of $500,000 and a target bonus of 75% of base salary.
  • Maestas will receive a non-qualified option to purchase 2,000,000 Class A shares, vesting over four years.
  • The Board approved the Inducement Plan on June 28, 2026, reserving 5,500,000 shares.

The filing

CompanyRani Therapeutics Holdings, Inc. (RANI)
Form8-K, current report
Filed with the SECJun 29, 2026, 6:54 PM ET
Accession number0001856725-26-000003

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.